The enzymatic activity of CYP2B6 plays a vital role in metabolizing various antidepressants, such as sertraline. Variations in the CYP2B6 gene can significantly alter how individuals respond to these medications. Identifying these genetic differences sheds light on tailoring treatment strategies to a more personalized level.
Recent research, conducted on a sizable cohort, unveiled the profound impact of CYP2B6 polymorphisms on antidepressant efficacy and safety, particularly sertraline. Depending on the presence or absence of certain genetic alleles, patients may experience altered drug exposure levels. This can directly influence the therapeutic benefits and the potential for adverse reactions.
For clinicians, assessing a patient's CYP2B6 genetic makeup prior to prescribing sertraline or other antidepressants is paramount. Such genetic insights allow for the customization of drug dosages. The goal is to enhance the efficacy of treatmen...
_____
If you are a member of our Association, please log in below to continue reading our exclusive content.
Not a member yet? Discover the benefits of joining our network and gain access to exclusive content like this for only $29.95 per month. Learn More and Sign Up
